Pfizer: completes acquisition of Biohaven Pharmaceuticals
(CercleFinance.com) - Pfizer has announced that it has completed its acquisition of Biohaven Pharmaceutical Holding Company, the maker of NURTEC ODT (rimegepant), a novel antimigraine treatment approved for the acute treatment and prevention of episodic migraine in adults.
The acquisition brings Pfizer a portfolio of promising calcitonin gene-related peptide (CGRP) receptor antagonists, including Rimegepant, Zavegepant and a portfolio of preclinical CGRP assets.
The success of NURTEC ODT, combined with Biohaven's CGRP pipeline, will strengthen Pfizer's innovative pipeline in internal medicine through 2030 and beyond, it said.
Pfizer has acquired all of Biohaven's outstanding shares that it did not already own for 148.50 dollars per share, in a transaction worth about 11.6 billion dollars. As a result of the acquisition, Biohaven becomes a wholly owned subsidiary of Pfizer.
Copyright (c) 2022 CercleFinance.com. All rights reserved.